A Phase I Study of Doxorubicin-loaded Anti-EGFR Immunoliposomes in Patients With Advanced Solid Tumors
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cetuximab-doxorubicin immunoliposome (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Sep 2014 Biomarkers information updated
- 23 Oct 2012 New trial record